Last reviewed · How we verify
Lisaftoclax (APG-2575)
Lisaftoclax is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells.
Lisaftoclax is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Acute myeloid leukemia (AML).
At a glance
| Generic name | Lisaftoclax (APG-2575) |
|---|---|
| Also known as | Induction phase, Maintenance phase |
| Sponsor | Ascentage Pharma Group Inc. |
| Drug class | BCL-2/BCL-xL inhibitor |
| Target | BCL-2, BCL-xL |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lisaftoclax (APG-2575) is a selective inhibitor of BCL-2 and BCL-xL, anti-apoptotic proteins that allow cancer cells to evade programmed cell death. By blocking these proteins, the drug restores the intrinsic apoptotic pathway, forcing cancer cells to undergo apoptosis. This mechanism is particularly relevant in hematologic malignancies where BCL-2 overexpression drives survival.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Acute myeloid leukemia (AML)
Common side effects
- Tumor lysis syndrome
- Neutropenia
- Thrombocytopenia
- Anemia
- Diarrhea
- Nausea
Key clinical trials
- Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL (PHASE2)
- Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma (PHASE2)
- A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. (PHASE1, PHASE2)
- Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease (PHASE2)
- A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia (PHASE3)
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). (PHASE3)
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL (PHASE2)
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lisaftoclax (APG-2575) CI brief — competitive landscape report
- Lisaftoclax (APG-2575) updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI